«Dollar - value
share repurchases amounted to $ 134.4 billion over the second quarter (July), which represented a 6.9 % decline from the first quarter (April) and a 0.4 % decline year - over-year,» FactSet's Andrew Birstingl notes.
As a corporation, KKR plans to pay an annualized dividend of 50 cents per common share and increase its authorized
share repurchase amount to $ 500 million.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the
amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market
share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its
share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The price to cash flow ratio would provide a better idea of the
amount of money available to management for further research and development, marketing support, debt reduction, dividends,
share repurchases, and more.
Among the 1,900 companies that have
repurchased their
shares since 2010, buybacks and dividends
amounted to 113 percent of their capital spending, compared with 60 percent in 2000 and 38 percent in 1990.
«RESOLVED, that the shareholders hereby approve, on an advisory basis, High River's proposal that Apple commit to completing not less than $ 50 billion of
share repurchases during Apple's fiscal year ending September 27, 2014 (and increase the
amount authorized for
share repurchases under its Capital Return Program accordingly).»
When a board of directors authorizes a
share repurchase program, it typically states either the number of
shares the company is interested in buying back or a dollar
amount it will spend on its stock buyback.
In addition, shareholders will be requested to approve a new
share repurchase authority, to which it has allocated a total
amount of PLN 250 million; the authority does not have a specified time - limit, rather, will be authorized «until such time the allocated funds are exhausted».
And then lastly, we feel great about the
amount of cash that this business continues to kick off, allowing us to reinvest in this low risk, high return new unit growth and the infrastructure to support it, while continuing to pay a competitive and over time, growing dividend, as well as consistent, robust
share repurchases.
If the company offers a dividend reinvestment plan, the
amount can be paid out by the company as cash for further
shares or
share repurchase.
A stock buyback, or
repurchase, occurs when a company buys its own
shares off the market and therefore reduces the
amount of stock outstanding.
The profit
amount can be used in business expansion, new project, acquiring a new company,
share repurchase etc..
According to the 10Q, the company is authorized to
repurchase 172,196
shares under a stock
repurchase plan but this is an immaterial
amount in the context of the 8.9 M
shares on issue and the plan has been in existence since 2002.
When a board of directors authorizes a
share repurchase program, it typically states either the number of
shares the company is interested in buying back or a dollar
amount it will spend on its stock buyback.
Not to mention, the company has
repurchased a consistent
amount of
shares, with $ 450 million allocated this year.
The timing and
amount of
shares repurchased will be determined at management's discretion, depending upon its evaluation of market conditions and other factors.
This is where analysts can also find the
amount of dividends paid and / or dollar value of
shares repurchased.
Hi, Shareholders equity is negative due to the large
amount of
share repurchases.
Find the
amount paid in dividends in total, and add to that the
amount paid towards
share repurchases.
Over the longest term, your results will be superior either because the market eventually returns the price to its fair value, or because for as long as its under its fair value, your reinvested dividends or the company's
share repurchases will be able to buy more
shares for the same
amount of money.